Forsinkede kurser. Sist oppdatert: lørdag 20. april  

19/03-2019 11:58:38: (TRVX) Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring

Oslo, Norway, 19 March 2019 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard-to-treat solid
tumors, announces that members of its senior management team is invited to
present at upcoming conferences.
13th Annual BIO-Europe Spring, Vienna, Austria
Date: 25 March 2019
Presenter: Øystein Soug (CEO)
Panel discussion:
-    Art of multitrack deal: Keys to maximizing the value of your company
-    Time: 14:45 CET
DNB's 15th Annual Small & Medium Enterprises (SME) Conference, Oslo, Norway
Date: 4 April 2019
Presenter: Øystein Soug (CEO)
-    Time: 13:45 CET
3rd Annual European Neoantigen Summit, Amsterdam, The Netherlands
Date: 25 April 2019
Presenter: Erik Digman Wiklund (CBO)
-    Title: TG Mutant RAS Neoantigen Vaccine: Signal of Clinical Benefit in
Resected Pancreatic Cancer
-    Time: 12:00 CET
Presentations will be available to download at (
-Presentations/events/default.aspx) after the event.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum - Corporate Communications
Phone: +47 9300 1773
About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard-to-treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.

Targovax's lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102's targeted path-to-market indication
is mesothelioma, where the virus is currently being tested in a randomized phase
II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma,
is expected to produce important proof-of-concept immune activation data in
heavily pre-treated patients.

Targovax is also developing a neo-antigen cancer vaccine targeting tumors with
oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program
has shown strong RAS-specific immune activation and a signal of clinical
efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next
generation product candidate, TG02 is currently tested in a phase I trial in
colorectal cancer, both as monotherapy and in combination with Keytruda (an anti
-PD1 check point inhibitor).

Ekstern link:

Nyheten er levert av OBI.